Minocycline Hydrochloride Dihydrate Aurobindo

Minocycline Hydrochloride, the active ingredient in Minocycline Hydrochloride Dihydrate Aurobindo, is a tetracycline antibiotic presented as an oral formulation for systemic use. Originating from the EU market, it is indicated for bacterial infections such as acne vulgaris, rickettsial diseases, chlamydial infections, respiratory and urinary tract infections in suitable patients.

GNH USA supplies Minocycline Hydrochloride Dihydrate Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Minocycline Hydrochloride is a broad‑spectrum tetracycline antibiotic used to treat bacterial infections affecting the skin, respiratory system, urinary tract and certain intracellular pathogens.

Acne vulgaris: reduces inflammatory lesions and bacterial colonisation. Rickettsial infections: eradicates causative Rickettsia species and limits disease progression. Chlamydial infections: eliminates Chlamydia trachomatis and improves clinical symptoms. Respiratory tract infections: treats community‑acquired pneumonia and bronchitis caused by susceptible bacteria. Urinary tract infections: clears susceptible uropathogens and resolves infection signs.

Minocycline Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea, vomiting, or abdominal discomfort. - Photosensitivity: increased sensitivity to sunlight. - Dizziness or vertigo. - Skin discoloration: mild hyperpigmentation.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, Stevens‑Johnson syndrome, or anaphylaxis. - Hepatotoxicity: significant liver injury or elevated enzymes. - Hematologic abnormalities: aplastic anemia, leukopenia, or thrombocytopenia. - Intracranial hypertension: headache, visual disturbances, or papilledema.

When prescribing Minocycline Hydrochloride, clinicians should consider several safety precautions to minimise risks. - Pregnancy: avoid use unless clearly needed, as fetal safety data are limited. - Breastfeeding: assess risk versus benefit; drug may be excreted in milk. - Liver disease: monitor hepatic function and adjust therapy if needed. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Drug‑induced photosensitivity: advise patients to limit sun exposure and use protective clothing. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Minocycline Hydrochloride can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Antacids containing aluminum, calcium, or magnesium: reduce absorption of minocycline. - Oral iron supplements: chelate the drug and markedly decrease its bioavailability. - Warfarin: may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Isotretinoin: combined use may increase risk of intracranial hypertension. - Cyclosporine: may raise serum concentrations of minocycline. - Oral contraceptives: may reduce efficacy of the contraceptive, increasing pregnancy risk.